Jacobs Levy Equity Management’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-128,654
| Closed | -$6.22M | – | 1145 |
|
|
2025
Q1 | $6.22M | Hold |
128,654
| – | – | 0.02% | 416 |
|
|
2024
Q4 | $4.97M | Hold |
128,654
| – | – | 0.02% | 434 |
|
|
2024
Q3 | $5.79M | Sell |
128,654
-357
| -0.3% | -$16.1K | 0.02% | 420 |
|
|
2024
Q2 | $4.47M | Hold |
129,011
| – | – | 0.02% | 475 |
|
|
2024
Q1 | $3.73M | Hold |
129,011
| – | – | 0.02% | 482 |
|
|
2023
Q4 | $2.96M | Hold |
129,011
| – | – | 0.01% | 535 |
|
|
2023
Q3 | $2.15M | Sell |
129,011
-17,476
| -12% | -$292K | 0.01% | 551 |
|
|
2023
Q2 | $4.05M | Sell |
146,487
-74,504
| -34% | -$2.06M | 0.02% | 441 |
|
|
2023
Q1 | $5.08M | Sell |
220,991
-63,124
| -22% | -$1.45M | 0.03% | 395 |
|
|
2022
Q4 | $3.1M | Buy |
284,115
+29,775
| +12% | +$325K | 0.02% | 474 |
|
|
2022
Q3 | $2.14M | Buy |
+254,340
| New | +$2.14M | 0.02% | 543 |
|
|
2020
Q3 | – | Sell |
-68,279
| Closed | -$1.21M | – | 1095 |
|
|
2020
Q2 | $1.21M | Sell |
68,279
-4,078
| -6% | -$72K | 0.01% | 636 |
|
|
2020
Q1 | $511K | Sell |
72,357
-19,474
| -21% | -$138K | 0.01% | 751 |
|
|
2019
Q4 | $647K | Buy |
91,831
+78,021
| +565% | +$550K | 0.01% | 752 |
|
|
2019
Q3 | $166K | Buy |
+13,810
| New | +$166K | ﹤0.01% | 861 |
|
|
2019
Q2 | – | Sell |
-21,700
| Closed | -$273K | – | 1010 |
|
|
2019
Q1 | $273K | Sell |
21,700
-6,700
| -24% | -$84.3K | ﹤0.01% | 851 |
|
|
2018
Q4 | $191K | Buy |
28,400
+1,900
| +7% | +$12.8K | ﹤0.01% | 892 |
|
|
2018
Q3 | $273K | Buy |
+26,500
| New | +$273K | ﹤0.01% | 878 |
|